4017 | Humans (MeSH) |
3962 | Animals (MeSH) |
2102 | Male (MeSH) |
1607 | Female (MeSH) |
1409 | Mice (MeSH) |
1036 | Rats (MeSH) |
1012 | Models, Biological (MeSH) |
627 | Adult (MeSH) |
589 | Middle Aged (MeSH) |
511 | Disease Models, Animal (MeSH) |
500 | Cell Line, Tumor (MeSH) |
485 | Antineoplastic Agents (pharmacology) |
484 | Dose-Response Relationship, Drug (MeSH) |
481 | Cells, Cultured (MeSH) |
446 | Time Factors (MeSH) |
424 | Apoptosis (drug effects) |
394 | Mice, Inbred C57BL (MeSH) |
393 | Rats, Sprague-Dawley (MeSH) |
374 | Aged (MeSH) |
350 | Cell Line (MeSH) |
339 | Treatment Outcome (MeSH) |
331 | Rats, Wistar (MeSH) |
325 | Signal Transduction (drug effects) |
315 | Cell Proliferation (drug effects) |
315 | Anti-Bacterial Agents (pharmacology) |
287 | Anti-Inflammatory Agents (pharmacology) |
281 | Amino Acid Sequence (MeSH) |
280 | Tumor Necrosis Factor-alpha (antagonists & inhibitors) |
275 | Signal Transduction (MeSH) |
275 | Cell Survival (drug effects) |
271 | Hypoglycemic Agents (pharmacology) |
270 | Mice, Inbred BALB C (MeSH) |
266 | Molecular Sequence Data (MeSH) |
256 | Biological Availability (MeSH) |
250 | Cytokines (metabolism) |
244 | Antineoplastic Agents (therapeutic use) |
234 | Hypoglycemic Agents (therapeutic use) |
217 | Case-Control Studies (MeSH) |
211 | Hypoglycemic Agents (administration & dosage) |
195 | Microbial Sensitivity Tests (MeSH) |
191 | Blood Glucose (metabolism) |
183 | Biological Transport (MeSH) |
179 | Tumor Necrosis Factor-alpha (metabolism) |
179 | In Vitro Techniques (MeSH) |
177 | Anti-Inflammatory Agents (therapeutic use) |
173 | Neuroprotective Agents (pharmacology) |
170 | Immunosuppressive Agents (therapeutic use) |
169 | Peptides (chemistry) |
169 | NF-kappa B (metabolism) |
169 | Diabetes Mellitus, Type 2 (drug therapy) |
169 | Biological Products (therapeutic use) |
168 | Insulin (administration & dosage) |
167 | RNA, Messenger (metabolism) |
167 | Administration, Oral (MeSH) |
166 | Phosphorylation (MeSH) |
166 | Adolescent (MeSH) |
164 | Oxidative Stress (drug effects) |
163 | Blotting, Western (MeSH) |
162 | Plant Extracts (pharmacology) |
160 | Kinetics (MeSH) |
160 | Biological Transport (drug effects) |
160 | Arthritis, Rheumatoid (drug therapy) |
155 | Structure-Activity Relationship (MeSH) |
154 | Antirheumatic Agents (therapeutic use) |
152 | Gene Expression Regulation (drug effects) |
151 | Neoplasms (drug therapy) |
150 | Antibodies, Monoclonal (therapeutic use) |
148 | Peptides (pharmacology) |
147 | Drug Therapy, Combination (MeSH) |
146 | Antineoplastic Agents (chemistry) |
144 | Young Adult (MeSH) |
143 | Enzyme Inhibitors (pharmacology) |
140 | Tumor Cells, Cultured (MeSH) |
140 | Insulin (metabolism) |
136 | Insulin (pharmacology) |
135 | Liver (drug effects) |
134 | Antioxidants (pharmacology) |
133 | Biomarkers (blood) |
132 | Liver (metabolism) |
130 | Mice, Nude (MeSH) |
130 | Insulin (blood) |
126 | Reactive Oxygen Species (metabolism) |
125 | Glutathione (metabolism) |
121 | Risk Factors (MeSH) |
121 | Apoptosis (MeSH) |
120 | Transfection (MeSH) |
120 | Mutation (MeSH) |
120 | Mice, Knockout (MeSH) |
117 | Antifungal Agents (pharmacology) |
116 | Glucose (metabolism) |
115 | Molecular Structure (MeSH) |
115 | Gene Expression Regulation (MeSH) |
114 | Plant Diseases (microbiology) |
112 | Immunosuppressive Agents (pharmacology) |
110 | Insulin (therapeutic use) |
109 | Drug Design (MeSH) |
108 | Child (MeSH) |
106 | Protein Binding (MeSH) |
106 | Drug Delivery Systems (MeSH) |
106 | Diabetes Mellitus, Type 1 (drug therapy) |
106 | Antiviral Agents (pharmacology) |
105 | Neurons (drug effects) |
104 | Xenograft Model Antitumor Assays (MeSH) |
104 | Blood Glucose (drug effects) |
103 | Biological Assay (MeSH) |
102 | Disease Progression (MeSH) |
102 | Anti-Inflammatory Agents, Non-Steroidal (pharmacology) |
101 | Protective Agents (pharmacology) |
100 | Reverse Transcriptase Polymerase Chain Reaction (MeSH) |
100 | Enzyme-Linked Immunosorbent Assay (MeSH) |
99 | Cell Movement (drug effects) |
98 | Nitric Oxide (metabolism) |
98 | Inflammation (drug therapy) |
98 | Immunohistochemistry (MeSH) |
98 | Drug Administration Schedule (MeSH) |
98 | Computer Simulation (MeSH) |
98 | Caspase 3 (metabolism) |
97 | Rabbits (MeSH) |
97 | Mice, Transgenic (MeSH) |
97 | Clinical Trials as Topic (MeSH) |
95 | Neoplasms (metabolism) |
95 | Calcium (metabolism) |
95 | Base Sequence (MeSH) |
95 | Aged, 80 and over (MeSH) |
94 | Signal Transduction (physiology) |
94 | Neurons (metabolism) |
94 | Brain (metabolism) |
94 | Algorithms (MeSH) |
93 | Inflammation (prevention & control) |
93 | Gene Expression (MeSH) |
93 | Drug Synergism (MeSH) |
92 | Inflammation (metabolism) |
92 | Cattle (MeSH) |
91 | Prospective Studies (MeSH) |
91 | Pregnancy (MeSH) |
91 | Antineoplastic Agents (administration & dosage) |
90 | Blood Glucose (analysis) |
89 | RNA, Messenger (genetics) |
89 | Interleukin-6 (metabolism) |
88 | Retrospective Studies (MeSH) |
88 | Neuroprotective Agents (therapeutic use) |
88 | Anti-Infective Agents (pharmacology) |
87 | Macrophages (drug effects) |
87 | Inflammation Mediators (metabolism) |
87 | Cell Proliferation (MeSH) |
87 | Anti-Bacterial Agents (chemistry) |
86 | Models, Molecular (MeSH) |
86 | Macrophages (metabolism) |
86 | Bacterial Proteins (genetics) |
85 | Severity of Illness Index (MeSH) |
85 | Peptide Fragments (pharmacology) |
84 | Swine (MeSH) |
84 | Hydrogen-Ion Concentration (MeSH) |
83 | Recombinant Proteins (pharmacology) |
83 | Cell Division (drug effects) |
82 | Pest Control, Biological (MeSH) |
82 | Chromatography, High Pressure Liquid (MeSH) |
81 | Vasodilator Agents (pharmacology) |
81 | Insulin Resistance (MeSH) |
81 | Hypoglycemic Agents (pharmacokinetics) |
81 | Antiviral Agents (therapeutic use) |
80 | Random Allocation (MeSH) |
80 | Phytotherapy (MeSH) |
80 | Graft Rejection (prevention & control) |
80 | Biological Products (pharmacology) |
80 | Anti-Bacterial Agents (therapeutic use) |
79 | Proto-Oncogene Proteins c-bcl-2 (metabolism) |
79 | Phosphorylation (drug effects) |
79 | Peptides (metabolism) |
79 | Gene Expression Profiling (MeSH) |
79 | Brain (drug effects) |
79 | Antineoplastic Agents, Phytogenic (pharmacology) |
78 | Reproducibility of Results (MeSH) |
78 | Immunosuppressive Agents (administration & dosage) |
77 | Drug Screening Assays, Antitumor (MeSH) |
77 | Biological Control Agents (MeSH) |
76 | Diabetes Mellitus, Experimental (drug therapy) |
76 | Cytokines (blood) |
76 | Cyclosporine (therapeutic use) |
76 | Bacterial Proteins (metabolism) |
75 | Phenotype (MeSH) |
75 | Oligopeptides (pharmacology) |
75 | Infliximab (MeSH) |
75 | Drug Evaluation, Preclinical (MeSH) |
75 | Area Under Curve (MeSH) |
75 | Anti-Inflammatory Agents, Non-Steroidal (therapeutic use) |
74 | Breast Neoplasms (drug therapy) |
74 | Analysis of Variance (MeSH) |
73 | Proto-Oncogene Proteins c-akt (metabolism) |
73 | Ligands (MeSH) |
72 | Neoplasms (pathology) |
72 | Lipopolysaccharides (pharmacology) |
72 | HeLa Cells (MeSH) |
72 | Diabetes Mellitus, Type 1 (blood) |
71 | Particle Size (MeSH) |
71 | Gene Expression Regulation, Neoplastic (drug effects) |
71 | Etanercept (MeSH) |
71 | Cloning, Molecular (MeSH) |
71 | Cell Membrane (metabolism) |
70 | Vascular Endothelial Growth Factor A (metabolism) |
70 | Up-Regulation (MeSH) |
70 | Tumor Necrosis Factor-alpha (immunology) |
70 | Neovascularization, Pathologic (prevention & control) |
70 | Liver (pathology) |
70 | Immunosuppressive Agents (pharmacokinetics) |
70 | Flow Cytometry (MeSH) |
70 | Cell Cycle (drug effects) |
70 | Blood Pressure (drug effects) |
69 | Peptides, Cyclic (pharmacology) |
69 | Follow-Up Studies (MeSH) |
68 | Recombinant Proteins (MeSH) |
68 | Randomized Controlled Trials as Topic (MeSH) |
67 | Prognosis (MeSH) |
67 | Gene Expression (drug effects) |
67 | Breast Neoplasms (pathology) |
66 | Endothelium, Vascular (drug effects) |
66 | Drug Carriers (chemistry) |
66 | Diabetes Mellitus, Type 2 (metabolism) |
66 | Cyclosporine (pharmacokinetics) |
65 | Tissue Distribution (MeSH) |
65 | Mitochondria (metabolism) |
65 | Cell Survival (MeSH) |
65 | Antineoplastic Agents (chemical synthesis) |
64 | Hypoglycemic Agents (adverse effects) |
64 | Cytokines (genetics) |
64 | Biological Products (adverse effects) |
63 | Plant Diseases (prevention & control) |
63 | Lung (drug effects) |
62 | Cytokines (immunology) |
62 | Antibodies, Monoclonal, Humanized (therapeutic use) |
62 | Antibodies, Monoclonal, Humanized (MeSH) |
61 | Sequence Analysis, DNA (MeSH) |
61 | Rats, Inbred Strains (MeSH) |
61 | Oxidative Stress (MeSH) |
61 | Gene Expression Regulation, Neoplastic (MeSH) |
61 | Down-Regulation (MeSH) |
61 | Breast Neoplasms (metabolism) |
61 | Binding Sites (MeSH) |
61 | Antirheumatic Agents (adverse effects) |
60 | Mitogen-Activated Protein Kinases (metabolism) |
60 | Hypoglycemic Agents (chemistry) |
60 | Enzyme Activation (drug effects) |
60 | Cell Differentiation (drug effects) |
60 | Antioxidants (metabolism) |
59 | T-Lymphocytes (immunology) |
59 | Protein Kinase Inhibitors (pharmacology) |
59 | Phylogeny (MeSH) |
59 | Nanoparticles (chemistry) |
59 | Down-Regulation (drug effects) |
59 | Cyclosporine (pharmacology) |
59 | Body Weight (drug effects) |
59 | Antibodies, Monoclonal (adverse effects) |
58 | Psoriasis (drug therapy) |
58 | Predictive Value of Tests (MeSH) |
58 | Mitochondria (drug effects) |
58 | Cyclosporine (administration & dosage) |
58 | Antioxidants (therapeutic use) |
57 | Tumor Necrosis Factor-alpha (pharmacology) |
57 | Oligopeptides (chemistry) |
57 | Insulin Secretion (MeSH) |
56 | Myocardium (metabolism) |
56 | Lung (pathology) |
56 | Caspases (metabolism) |
56 | Bacteria (drug effects) |
56 | Antifungal Agents (metabolism) |
55 | Up-Regulation (drug effects) |
55 | Plant Extracts (chemistry) |
55 | Neoplasms (prevention & control) |
55 | Insulin (pharmacokinetics) |
55 | Immunoglobulin G (therapeutic use) |
55 | Enzyme Activation (MeSH) |
55 | Diabetes Mellitus, Type 2 (blood) |
55 | Cytokines (biosynthesis) |
55 | Apoptosis (physiology) |
54 | Receptors, Tumor Necrosis Factor (therapeutic use) |
54 | Plant Extracts (therapeutic use) |
54 | Mice, Inbred ICR (MeSH) |
54 | Immunosuppressive Agents (adverse effects) |
54 | Dogs (MeSH) |
54 | Cricetinae (MeSH) |
54 | Antimicrobial Cationic Peptides (pharmacology) |
53 | Tumor Necrosis Factor-alpha (genetics) |
53 | Peptide Hydrolases (metabolism) |
53 | Oxidation-Reduction (MeSH) |
53 | Neoplasm Transplantation (MeSH) |
53 | Hippocampus (drug effects) |
53 | Cell Membrane (drug effects) |
53 | Biofilms (drug effects) |
53 | Antineoplastic Agents (adverse effects) |
53 | Antihypertensive Agents (pharmacology) |
53 | Anti-Inflammatory Agents (administration & dosage) |
52 | Lipopeptides (pharmacology) |
52 | Hypertension (drug therapy) |
52 | HEK293 Cells (MeSH) |
52 | Cell Death (drug effects) |
52 | Cardiotonic Agents (pharmacology) |
52 | Biomarkers (metabolism) |
52 | Amyloid beta-Peptides (metabolism) |
52 | Alzheimer Disease (metabolism) |
52 | AMP-Activated Protein Kinases (metabolism) |
51 | Survival Analysis (MeSH) |
51 | Superoxide Dismutase (metabolism) |
51 | Recombinant Proteins (metabolism) |
51 | Lipid Peroxidation (drug effects) |
51 | Fibroblasts (drug effects) |
51 | Drug Stability (MeSH) |
51 | Child, Preschool (MeSH) |
51 | Anti-Bacterial Agents (administration & dosage) |
50 | Protein-Serine-Threonine Kinases (metabolism) |
50 | Protein Conformation (MeSH) |
50 | Peptides, Cyclic (chemistry) |
50 | NF-kappa B (antagonists & inhibitors) |
50 | Escherichia coli (genetics) |
50 | Diabetes Mellitus, Experimental (metabolism) |
50 | Chronic Disease (MeSH) |
50 | Anticarcinogenic Agents (pharmacology) |
50 | Anti-Inflammatory Agents (chemistry) |
49 | T-Lymphocytes (drug effects) |
49 | Real-Time Polymerase Chain Reaction (MeSH) |
49 | Molecular Weight (MeSH) |
49 | Macrophages (immunology) |
49 | Interleukin-1beta (metabolism) |
49 | Inflammation (pathology) |
49 | Endothelium, Vascular (metabolism) |
49 | Drug Interactions (MeSH) |
49 | Drug Delivery Systems (methods) |
49 | Angiogenesis Inhibitors (pharmacology) |
48 | Molecular Targeted Therapy (MeSH) |
48 | Methotrexate (therapeutic use) |
48 | Mass Spectrometry (MeSH) |
48 | Kidney (drug effects) |
48 | Insulin Infusion Systems (MeSH) |
48 | Injections, Subcutaneous (MeSH) |
48 | Double-Blind Method (MeSH) |
48 | Animals, Newborn (MeSH) |
47 | Tumor Necrosis Factor-alpha (blood) |
47 | Temperature (MeSH) |
47 | Staphylococcus aureus (drug effects) |
47 | Solubility (MeSH) |
47 | Polyethylene Glycols (chemistry) |
47 | Hippocampus (metabolism) |
47 | Flavonoids (pharmacology) |
47 | Antibodies, Monoclonal (pharmacology) |
47 | Antibiosis (MeSH) |
46 | Transcription Factors (metabolism) |
46 | Pest Control, Biological (methods) |
46 | Peptide Fragments (metabolism) |
46 | Drug Carriers (MeSH) |
46 | Adalimumab (MeSH) |
45 | STAT3 Transcription Factor (metabolism) |
45 | Neurotransmitter Agents (physiology) |
45 | Intestinal Mucosa (metabolism) |
45 | Inflammation (immunology) |
44 | p38 Mitogen-Activated Protein Kinases (metabolism) |
44 | Vasodilation (drug effects) |
44 | Vasoconstrictor Agents (pharmacology) |
44 | Polymerase Chain Reaction (MeSH) |
44 | Obesity (metabolism) |
44 | Hep G2 Cells (MeSH) |
44 | Genotype (MeSH) |
44 | Escherichia coli (drug effects) |
44 | Antineoplastic Agents (pharmacokinetics) |
44 | Antifungal Agents (chemistry) |
43 | bcl-2-Associated X Protein (metabolism) |
43 | Dietary Supplements (MeSH) |
42 | Species Specificity (MeSH) |
42 | Protein Structure, Tertiary (MeSH) |
42 | Protective Agents (therapeutic use) |
42 | Neurons (pathology) |
42 | Lung (metabolism) |
42 | Inflammation (MeSH) |
42 | Immunologic Factors (therapeutic use) |
42 | Hypoglycemia (prevention & control) |
42 | Hyperglycemia (prevention & control) |
42 | Cyclic AMP (metabolism) |
42 | Chemistry, Pharmaceutical (MeSH) |
42 | Cardiovascular Diseases (prevention & control) |
42 | Antibodies, Monoclonal (administration & dosage) |
42 | Adipocytes (metabolism) |
41 | Tumor Necrosis Factor-alpha (biosynthesis) |
41 | Surface Properties (MeSH) |
41 | Recombinant Fusion Proteins (genetics) |
41 | RNA Interference (MeSH) |
41 | RAW 264.7 Cells (MeSH) |
41 | Myocytes, Cardiac (drug effects) |
41 | Molecular Docking Simulation (MeSH) |
41 | Matrix Metalloproteinase 9 (metabolism) |
41 | Lipopeptides (metabolism) |
41 | Interleukin-6 (blood) |
41 | Half-Life (MeSH) |
41 | Glucose Tolerance Test (MeSH) |
41 | Fungi (drug effects) |
41 | Drug Combinations (MeSH) |
41 | Cyclooxygenase 2 (metabolism) |
41 | Combined Modality Therapy (MeSH) |
41 | Cohort Studies (MeSH) |
41 | Biological Transport (physiology) |
41 | Arthritis, Rheumatoid (immunology) |
41 | Anti-Bacterial Agents (metabolism) |
40 | Recombinant Proteins (therapeutic use) |
40 | Recombinant Proteins (genetics) |
40 | RNA, Messenger (biosynthesis) |
40 | Phosphatidylinositol 3-Kinases (metabolism) |
40 | Peptides (administration & dosage) |
40 | Peptide Fragments (chemistry) |
40 | Inhibitory Concentration 50 (MeSH) |
40 | Infant, Newborn (MeSH) |
40 | Heart (drug effects) |
40 | Fibroblasts (metabolism) |
40 | Endothelial Cells (metabolism) |
40 | DNA-Binding Proteins (metabolism) |
40 | Cytokines (antagonists & inhibitors) |
40 | Cell Differentiation (MeSH) |
40 | Caco-2 Cells (MeSH) |
40 | Behavior, Animal (drug effects) |
40 | Acetylcholine (pharmacology) |
39 | Sequence Homology, Amino Acid (MeSH) |
39 | Risk Assessment (MeSH) |
39 | Peptides (therapeutic use) |
39 | Neurotransmitter Agents (metabolism) |
39 | MAP Kinase Signaling System (drug effects) |
39 | Insulin (adverse effects) |
39 | Injections, Intravenous (MeSH) |
39 | Epithelial Cells (drug effects) |
39 | Biological Control Agents (pharmacology) |
39 | Anti-Infective Agents (chemistry) |
39 | Anti-Bacterial Agents (pharmacokinetics) |
39 | Alzheimer Disease (drug therapy) |
38 | Vancomycin (pharmacology) |
38 | Reperfusion Injury (prevention & control) |
38 | Peptides, Cyclic (metabolism) |
38 | Neutrophils (drug effects) |
38 | Lung Neoplasms (pathology) |
38 | Injections, Intraperitoneal (MeSH) |
38 | Homeostasis (MeSH) |
38 | Extracellular Signal-Regulated MAP Kinases (metabolism) |
38 | Drug Resistance, Neoplasm (MeSH) |
38 | Diabetes Mellitus (drug therapy) |
38 | Cross-Sectional Studies (MeSH) |
38 | Cell Nucleus (metabolism) |
38 | Biological Products (administration & dosage) |
38 | Antineoplastic Agents (metabolism) |
38 | Adenosine Triphosphate (metabolism) |
37 | Virus Replication (drug effects) |
37 | Sequence Alignment (MeSH) |
37 | Sensitivity and Specificity (MeSH) |
37 | Protein Kinase C (metabolism) |
37 | Prostatic Neoplasms (pathology) |
37 | Nitric Oxide Synthase Type II (metabolism) |
37 | Neoplasm Invasiveness (prevention & control) |
37 | Myocardium (pathology) |
37 | MCF-7 Cells (MeSH) |
37 | Lipopolysaccharides (MeSH) |
37 | Interferon-alpha (therapeutic use) |
37 | Inflammation (chemically induced) |
37 | Incidence (MeSH) |
37 | Endothelial Cells (drug effects) |
37 | Electrophoresis, Polyacrylamide Gel (MeSH) |
37 | Drug Liberation (MeSH) |
37 | Diabetes Mellitus, Type 2 (complications) |
37 | Cell Division (MeSH) |
37 | Bacillus (metabolism) |
37 | Alzheimer Disease (prevention & control) |
36 | Tumor Suppressor Protein p53 (metabolism) |
36 | Transcription, Genetic (MeSH) |
36 | Promoter Regions, Genetic (MeSH) |
36 | Obesity (drug therapy) |
36 | Neoplasms (therapy) |
36 | Myocytes, Cardiac (metabolism) |
36 | Microscopy, Fluorescence (MeSH) |
36 | Larva (drug effects) |
36 | Insulin-Secreting Cells (metabolism) |
36 | Inflammatory Bowel Diseases (drug therapy) |
36 | Diabetes Mellitus, Type 1 (metabolism) |
36 | Carrier Proteins (metabolism) |
36 | Biological Transport, Active (drug effects) |
36 | Antimicrobial Cationic Peptides (chemistry) |
36 | Antihypertensive Agents (therapeutic use) |
36 | Angiogenesis Inhibitors (therapeutic use) |
35 | Transforming Growth Factor beta (metabolism) |
35 | Transcription Factors (genetics) |
35 | Proteins (metabolism) |
35 | Neoplasm Invasiveness (MeSH) |
35 | Muscle, Smooth, Vascular (drug effects) |
35 | Matrix Metalloproteinase 2 (metabolism) |
35 | Lung Neoplasms (drug therapy) |
35 | Kidney (metabolism) |
35 | Immunologic Factors (pharmacology) |
35 | Imidazoles (pharmacology) |
35 | Hypertension (physiopathology) |
35 | Drug Compounding (MeSH) |
35 | DNA Damage (MeSH) |
35 | Brain (pathology) |
35 | Apoptosis Regulatory Proteins (metabolism) |
35 | Anti-Bacterial Agents (biosynthesis) |
35 | Adipose Tissue (metabolism) |
34 | Soil Microbiology (MeSH) |
34 | Pancreas, Artificial (MeSH) |
34 | Neutrophils (metabolism) |
34 | Neoplasms (genetics) |